Lupin receives approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.09%

Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Bromfenac Ophthalmic Solution, 0.09%, to market a generic equivalent of Bromday Ophthalmic Solution, 0.09%, of Bausch & Lomb Inc. This product will be manufactured at Lupin's Pithampur facility in India.

Bromfenac Ophthalmic Solution 0.09% (RLD Bromday) had estimated annual sales of USD 11 million in the U.S. (IQVIA MAT June 2023).

Shares of Lupin Limited was last trading in BSE at Rs. 1081.70 as compared to the previous close of Rs. 1076.95. The total number of shares traded during the day was 90529 in over 4824 trades.

The stock hit an intraday high of Rs. 1105.80 and intraday low of 1077.35. The net turnover during the day was Rs. 98894131.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 USFDA ANDA BromfenacOphthalmicSolution